Blog
RSS FeedPosted by Michael Wonder on 11 Apr 2024
170,000 people in England to have further treatment choice for preventing migraine attacks
11 April 2024 - In final draft guidance published today NICE has recommended atogepant, the first of a new type of ...
Posted by Michael Wonder on 11 Apr 2024
Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS
11 April 2024 - Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia. ...
Posted by Michael Wonder on 10 Apr 2024
Cabozantinib maleate in combination with nivolumab for the first-line treatment of patients with advanced renal cell carcinoma
10 April 2024 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) in combination with ...
Posted by Michael Wonder on 03 Apr 2024
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent, high microsatellite instability or mismatch repair deficiency endometrial cancer
3 April 2024 - NICE has published final evidence-based recommendations on the use of dostarlimab (Jemperli) in combination with platinum-based ...
Posted by Michael Wonder on 02 Apr 2024
Vamorolone for the treatment of patients with Duchenne muscular dystrophy
28 March 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Apr 2024
Relugolix–estradiol–norethisterone acetate for the treatment of patients with pain associated with endometriosis
28 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 27 Mar 2024
Satralizumab for the prevention of relapse in patients with a neuromyelitis optica spectrum disorder
27 March 2024 - NICE is unable to make a recommendation on the use of satralizumab (Enspryng) for the prevention of ...
Posted by Michael Wonder on 27 Mar 2024
Ritlecitinib tosylate for the treatment of people 12 years and over with alopecia areata
27 March 2024 - NICE has published final evidence-based recommendations on the use of ritlecitinib tosylate (Litfulo) for the treatment ...
Posted by Michael Wonder on 21 Mar 2024
Momelotinib dihydrochloride monohydrate for the treatment of patients with myelofibrosis-related splenomegaly or symptoms
20 March 2024 - NICE has published final evidence-based recommendations on momelotinib dihydrochloride monohydrate (Omjjara) for the treatment of aduklts ...
Posted by Michael Wonder on 14 Mar 2024
Exagamglogene autotemcel for the treatment of patients with sickle cell disease
14 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 13 Mar 2024
Dupilumab for the treatment of adults with moderate to severe prurigo nodularis
13 March 2024 - NICE has published final evidence-based recommendations on the use of dupilumab (Dupixent) for the treatment of ...
Posted by Michael Wonder on 13 Mar 2024
Fluocinolone acetonide for the treatment of patients with chronic diabetic macular oedema
13 March 2024 - NICE has published final evidence-based recommendations on the use of fluocinolone acetonide intravitreal implant (Iluvien) for ...
Posted by Michael Wonder on 12 Mar 2024
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
11 March 2024 - New one a day pill recommended on the same day the treatment was granted a licence ...
Posted by Michael Wonder on 07 Mar 2024
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
28 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Mar 2024
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments
6 March 2024 - NICE has published final evidence-based recommendations on the use of epcoritamab (Tepkinly) for the treatment of ...